Dr. David M. Schuster, a professor, nuclear radiologist, and researcher at the Winship Cancer Institute of Emory University, says if a man lives long enough, he will probably live with prostate cancer. Now, POSLUMA PET imaging is the first FDA-approved radio-hybrid drug for PET imaging of prostate cancers. This unique combination delivers a high-resolution image that illuminates cancer cells.